Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects With De Novo or Treatment Emergent Neuroendocrine Prostate Cancer

NCT04702737 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04702737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04702737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects With De Novo or Treatment Emergent Neuroendocrine Prostate Cancer
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
June 10, 2021
Completion date
July 22, 2024
Enrollment
41 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine prostate cancer